On Heels of $17 Billion SPAC Deal, Ginkgo Inks Collab with Synthetic Biology Firm – BioSpace

California synthetic biology firm Antheia has joined forces with Boston-based biotech companyGinkgo Bioworksto strengthen its efforts to develop and produce essential medicines to treat a wide range of diseases.

Antheia is looking to leverage Ginkgo's cell programming technology and high throughput enzyme design and screening capabilities to support its pipeline of critical active pharmaceutical ingredients (APIs) and key starting materials (KSMs).

Antheia creates complex, plant-inspired therapies through its whole-cell engineering approach to reconstruct complex molecules in yeast. As the company moves its activities to a more commercial scale, it continually invests in strain optimization strategies to ensure the highly efficient production of its target products.

Since most of the world's medicines come from nature, Antheia has developed a more efficient and lower-risk method of creating nature-inspired drugs that are easier, faster, and more efficient to manufacture. In addition to making essential medications more available, this method also prevents the wastage of natural resources and overharvesting.

"Antheia is at the cutting edge of synthetic biology innovation, and its whole-cell engineering platform is capable of producing entire classes of medicines that were previously inaccessible. We are thrilled that Ginkgo's platform can support innovators like Antheia as they create next generation manufacturing technologies for essential medicines," said Barry Canton, co-founder and chief technology officer at Ginkgo Bioworks, in astatement.

The partnership comes on the heels of Ginkgo's newly-inked$17 billion mergerwith Soaring Eagle Acquisition Corp a deal that is expected to add some $15 billion in estimated value to the former when it finalizes in the third quarter of 2021, subject to shareholder and regulatory clearances. Its completion also makes Ginkgo Bioworks a public company.

Ginkgo specializes in enzyme discovery, strain improvement, mammalian cell engineering, and cultured ingredients development, among others. Its solutions serve a wide range of industries, including pharmaceuticals, industrials, food, chemicals, and more.

Ginkgo's products are developed through two core technologies: Ginkgo Codebase (referring to its libraries of cell, enzymes, and genetic programs) and Ginkgo Foundries (referring to its automated biological factories).

Its partnership with Antheia makes it even more possible for critical medicine to be produced on-demand under more efficient and environment-friendly conditions. In addition, biomanufacturing pharmaceuticals have a greater advantage over traditional production methods in terms of cost, quality control, sustainability, and supply chain resilience and agility.

"Antheia is committed to using synthetic biology to enable more equitable access to essential medicines. By partnering with Ginkgo Bioworks, a global leader in organism engineering, we are greatly increasing our ability to develop essential medicines at the speed and scale necessary to drive change in global pharma supply chains," noted Kristy Hawkins, co-founder and CSO at Antheia.

Read more here:
On Heels of $17 Billion SPAC Deal, Ginkgo Inks Collab with Synthetic Biology Firm - BioSpace

Study uncovers molecular mechanisms that promote cell-to-cell adhesion and communication – News-Medical.net

A study led by Northwestern Medicine investigators has identified the molecular mechanisms within protein complexes that promote cell-to-cell adhesion and communication, according to findings published in the Proceedings of the National Academy of Sciences.

Sergey Troyanovsky, PhD, professor of Dermatology and of Cell and Developmental Biology, was senior author of the study.

Cadherins and catenins are proteins that form multiprotein complexes, helping bind cells together and stabilize cell-cell interactions, thereby forming different tissues. Those complexes, called cadherin-catenin complex (CCC), form clusters, but exactly how other CCC-associated proteins are recruited into these clusters and how they affect the overall clustering process has up until now remained understudied, according to Troyanovsky.

Using mass spectrometry and cross-linking, a proteomics approach which involves chemically "linking" two or more neighboring molecules by a covalent bond, the investigators discovered that most CCC-associated proteins interact with CCCs outside of adherens junctions, or protein complexes that include cadherin receptors. Furthermore, structural modeling revealed that there is limited space for CCC-associated proteins to form clusters in the first place.

Next, the investigators analyzed two example CCC-associated proteins essential for cell polarity and cell proliferation, and found that each protein formed separate CCC-associated clusters.

A431 cells expressing EcDn were briefly stained and then immediately imaged simultaneously in green and red channels.

The findings suggest that protein-driven CCC clustering plays a role in cell-to-cell adhesion, as well as enables cells to communicate with each other by synchronizing their signaling networks.

Different proteins which associate with CCC can sort cadherin into different populations of CCC clusters, and that's important because it's actually a mechanism of how signaling units can be equalized in different cells."

Sergey Troyanovsky, PhD, Member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Troyanovsky said the findings may also improve the understanding of the intracellular mechanisms that give rise to skin diseases, as most skin diseases are caused by defects in cell-to-cell adhesion within the epidermis.

Source:

Journal reference:

Troyanovsky, R.B., et al. (2021) Sorting of cadherincatenin-associated proteins into individual clusters. PNAS. doi.org/10.1073/pnas.2105550118.

Visit link:
Study uncovers molecular mechanisms that promote cell-to-cell adhesion and communication - News-Medical.net

FGI Night of Stars to Honor Established Designers and Other Talents – Yahoo Lifestyle

OUT AND ABOUT (HOPEFULLY): Just getting outdoors can be a celebration of sorts, but the Fashion Group International has grander plans for the return of its Night of Stars event this fall.

News that the gala is scheduled to be held in-person was considered a win in itself when revealed in May. Now organizers are detailing their all-out gala plans.

More from WWD

Slated for Oct. 13 at Cipriani South Street at Casa Cipriani, the 37th annual red carpet is being touted as The Evolutionaries. Honorees will include a mix of international designers and other enterprising talents.

Tommy Hilfiger will be the leading star, so to speak, as the recipient of the Superstar and Lifetime Achievement award. Monse founders and Oscar de la Rentas creative duo Fernando Garcia and Laura Kim will be honored as Vanguards.

To get a jump on the celebration, there will be a pre-party the night before the first of its kind on Oct. 12 that will be hosted by Garcia and Kim at the de la Renta boutique on Madison Avenue. Limited tickets will be available and the gathering will benefit the Fashion Group Foundation for its educational mission.

Fausto Puglisi, creative consultant for Roberto Cavalli, will be on hand at the annual awards event to receive the Fashion Star award. Luxury skin care specialist Augustinus Bader, a scientist, physician and authority in stem cell biology and regenerative medicine, is this years Beauty honoree.

Gabriela Hearst will be saluted with the Sustainability award, while Norma Kamali will be celebrated with the Founders Award. The designer expanded her portfolio by launching a home collection a few months ago.

Stylist Law Roach, who has worked with Cardi B, Zendaya, Celine Dion and other celebrities, will receive the Fashion Provacateur award from FGI. The Retail award will be given to the cereal and sneaker-selling Kith founder Ronnie Fieg. And Mastercards chief marketing and communications officer Raja Rajamannar will receive the Tech and Brand Innovation award.

Story continues

Provided coronavirus concerns do not result in substantial federal, state or local restrictions, Night of Stars will mark FGIs first IRL red carpet in two years. In adherence with CDC restrictions and guidelines, FGI is investigating prescreening for vaccinations, on-site testing and touchless entry to be sure that our guests feel protected and experience the luxury evening to which they are accustomed, according to James DAdamo, chairman of FGIs board.

While organizers have yet to reveal the presenters, the annual dinner has attracted power players in music, entertainment and fashion in years past. Artist and illustrator Ruben Toledo has once again created exclusive artwork for the invitations and a commemorative journal for the black-tie event.

FGIs president and chief executive officer Maryanne Grisz said, In a year of transformation, evolution and emotion, we are delighted to be together as a community once again. FGI celebrates these incredible visionaries, who, through their creativity, innovation and drive, represent true leadership, a deeper meaning around the event and where we are going as an industry.

Best of WWD

Sign up for WWD's Newsletter. For the latest news, follow us on Twitter, Facebook, and Instagram.

Go here to read the rest:
FGI Night of Stars to Honor Established Designers and Other Talents - Yahoo Lifestyle

Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate First-In-Human Trial of IO-108, a Novel Antagonist Antibody Targeting…

PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (Immune-Onc), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced that the U.S. Food and Drug Administration (FDA) has cleared the companys Investigational New Drug (IND) application for IO-108, a novel antagonist antibody targeting Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4) for the treatment of solid tumors. Preclinical data presented at the 2020 Society for Immunotherapy of Cancers annual meeting demonstrate that IO-108 functions as a myeloid checkpoint inhibitor. IO-108 reprograms immune-suppressive myeloid cells toward a pro-inflammatory phenotype, leading to enhanced innate and adaptive anti-tumor immunity.

"The clearance of the IO-108 IND represents another major milestone for Immune-Onc as we progress our pipeline of novel myeloid checkpoint inhibitors targeting the LILRB family of immune inhibitory receptors, said Charlene Liao, Ph.D., chief executive officer of Immune-Onc. We are highly encouraged by the strength of the preclinical data of IO-108 and are pleased that our expertise in LILRB biology and translational sciences enables us to advance this asset into the clinic. We look forward to initiating the trial to further understand the role of LILRBs in cancer, and to test the potential of IO-108 in treating patients with advanced solid tumors.

The Phase 1, multicenter, dose-escalation study will consist of a monotherapy cohort and a combination therapy cohort to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IO-108 alone and in combination with pembrolizumab, an anti-PD-1 antibody. Biomarkers will be assessed to enable a mechanistic understanding of clinical data and inform future trials. This study may also provide an opportunity to identify preliminary efficacy signals. After determination of the recommended Phase 2 dose, Immune-Onc plans to evaluate the efficacy, safety, and tolerability of IO-108 in combination with pembrolizumab and as monotherapy in indication-specific expansion cohorts.

IO-108 binds to LILRB2 with high affinity and specificity and blocks the interaction of LILRB2 with multiple ligands that are involved in cancer-associated immune suppression including HLA-G, ANGPTLs, SEMA4A, and CD1d. In preclinical studies, treatment of various primary human immune cell systems containing myeloid cells with IO-108 results in enhanced pro-inflammatory responses to multiple stimuli that are relevant to anti-tumor immunity. As a single agent, IO-108 reverses the anti-inflammatory myeloid cell phenotype that results from tumor conditioning and promotes the differentiation of monocytes into pro-inflammatory dendritic cells. Moreover, IO-108 potentiates the effect of PD-1 blocking antibodies on CD4+ T cell activation in co-cultures with allogeneic macrophages. In mouse models IO-108 inhibits the growth of solid tumors, which is associated with enhanced T cell responses. Together these data demonstrate that IO-108 has the potential to provide additive or synergistic benefit in combination with standard-of-care immunotherapies and/or immunogenic therapies for solid tumors that are both resistant and sensitive to T-cell checkpoint inhibitors.

ABOUT LILRB2 (ILT4)

LILRB2, also known as ILT4, is expressed mostly on myeloid cells, including monocytes, dendritic cells, macrophages, and neutrophils. In solid tumors, interaction of LILRB2 with tumor microenvironment (TME) relevant ligands, including HLA-G, ANGPTLs, SEMA4A, and CD1d, makes myeloid cells pro-tumorigenic (tolerating or promoting tumor growth) and promotes tumor immune evasion.

ABOUT IMMUNE-ONC THERAPEUTICS, INC.

Immune-Onc Therapeutics, Inc. (Immune-Onc) is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment.

Immune-Onc has a promising pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. Immune-Oncs focused platform approach has led to the development of several promising therapeutics across various stages of development, including IO-108 in Phase 1 clinical development for solid tumors and IO-202, a first-in-class antibody targeting LILRB4 (also known as ILT3), in Phase 1 clinical development for the treatment of acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). The company also plans to evaluate IO-202 in solid tumors. The U.S. Food and Drug Administration granted IO-202 Orphan Drug Designation for treatment of AML in October 2020. Additional assets in Immune-Oncs pipeline include IO-106, a first-in-class anti-LAIR1 antibody, and multiple undisclosed programs for solid tumors and hematologic malignancies.

The company has strategic research collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center, and has invested in proprietary models, assays, and tools to interrogate the biology and translate this cutting-edge research into the development of novel therapies. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit http://www.immune-onc.com and follow us on Twitter and LinkedIn.

Originally posted here:
Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate First-In-Human Trial of IO-108, a Novel Antagonist Antibody Targeting...

Berkeley Lights and Bayer announce a multi-year agreement aimed at revolutionizing the discovery of next-generation traits – Yahoo Finance

Agreement debuts Berkeley Lights rapid high-throughput functional screening capability to accelerate and expand the discovery and development of Bayer Crop Sciences seeds and traits product pipeline

EMERYVILLE, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI) a leader in the functional characterization of live biology, announced a multi-year agreement with Bayer to develop and perform high-throughput functional screening workflows aimed at accelerating and expanding the discovery of novel traits. Terms of the agreement were not disclosed.

Berkeley Lights will leverage its platform to screen individual variants of bioactives for Bayer in a massively high-throughput manner. The outcome will be a significant acceleration of the agricultural leaders pipeline for discovery and development of novel traits. This agreement marks the first application of Berkeley Lights technology for use in the agricultural sector.

After evaluating the technology landscape, it became clear that the Berkeley Lights Platform is uniquely positioned to enable Bayer Crop Science to deliver on our commitment for world-class innovation and standards in sustainability for farmers, consumers and the environment, said Brianna White, Head of Trait Design and Science for Bayer. Our agreement with Berkeley Lights to develop and perform high-throughput functional screening workflows will enable us to accelerate and expand our trait discovery program.

We are excited to support Bayer in the discovery and development of novel traits, said Eric Hobbs, PhD, chief executive officer of Berkeley Lights. This agreement is an example of Berkeley Lights executing on our commitment to deploy our technologies into new, large market segments. Our proprietary approach to high-throughput functional screening is applicable to a variety of sectors and applications even beyond agriculture, including antibody, therapeutic protein, and enzyme engineering for pharmaceutical, life science, and industrial products.

Story continues

About Berkeley LightsBerkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.

The Berkeley Lights Platform is FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

Forward-Looking StatementsTo the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Companys growth and evolution, including its ability to accelerate, expand and/or revolutionize the discovery of novel traits and to expand its technology approach to high-throughput functional screening into new sectors and applications, see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission.

Berkeley Lights Press Contactchristy.nguyen@berkeleylights.com

Investor Contactir@berkeleylights.com

Continue reading here:
Berkeley Lights and Bayer announce a multi-year agreement aimed at revolutionizing the discovery of next-generation traits - Yahoo Finance

UPMC-Pitt Researchers Receive Grant to Advance Liver Organoids – UPMC & Pitt Health Sciences News Blog – UPMC

Share this on:

Researchers from the University of Pittsburgh Liver Research Center, McGowan Institute for Regenerative Medicine and Carnegie Mellon Universitys (CMU) Computational Biology Department have been awarded almost $1.5 million from the National Science Foundation (NSF) to develop new approaches for producing liver organoids tiny, lab-grown human organs that have potential for disease modeling, drug discovery and transplantation.

Mouse models are often used for research on human diseases, but there is a gap between studies in cells and animals and translation to humans, said principal investigator Dr. Mo Ebrahimkhani, associate professor of pathology and bioengineering at Pitt and member of the Pittsburgh Liver Research Center and the McGowan Institute. Organoids help fill that gap because they can capture the complexity of our human organs and tissues.

Dr. Mo Ebrahimkhani

To grow these mini organs, researchers start with induced pluripotent stem cells (iPSCs), which are made from adult cells. iPSCs can turn into almost any cell type, and given the right signals at the right time, they can grow into complex 3D organoids of multiple tissue types.

Traditionally, organoid development is directed by adding a cocktail of chemicals at different times. But this trial-and-error approach is hard to optimize and can introduce variability among batches, hampering reproducibility and scalability of organoid production and making it difficult to compare findings across labs. Another problem is that development can stall, leaving cells with immature or abnormal characteristics or lacking blood vessels, which are important for transplantation applications.

These challenges prompted the NSFs call for research proposals that apply multidisciplinary approaches to understand processes of cellular differentiation during organ development and improve production of mature, functional cells or organoids.

Ebrahimkhani, in collaboration with Dr. Samira Kiani, co-principal investigator and associate professor of pathology at Pitt, and Dr. Ziv Bar-Joseph, professor of computational biology and machine learning who heads the Systems Biology Group at CMU, received funding to develop liver organoids that can be produced consistently and reliably. The researchers aim to program iPSCs with genetic instructions that guide cells to produce liver tissues with specified structure and function, rather than relying on external addition of growth factors.

We will develop programmable organoids with genetic circuits and switches, allowing them to sense the cell types and states, so they know when its the right time to turn on and turn off their programs, Ebrahimkhani explained.

The cells can be frozen, stored and shipped to different labs, he said. This will improve reproducibility, reliability and sharing of the science.

To generate genetic programs for liver organoids, the researchers aim to understand the processes that control organ development by combining two different tactics.

To improve lab-grown liver organoids, researchers will use computational analyses and genetic tools to understand and guide organ development. Credit: Emma Br

Our lab uses synthetic biology to manipulate genetic pathways in cells. By building these pathways, we understand the process, said Ebrahimkhani. Its like building a car from all the individual components. As I build the car, I understand how it functions.

Bar-Josephs lab will use computational analyses to reconstruct models that help explain how cells differentiate and interact with one another during organ development, an approach termed systems biology.

Systems biology is like trying to understand the car by taking it apart and looking at its individual components, said Bar-Joseph. In this research, we aim to combine synthetic biology and systems biology to understand organ development.

As part of the grant, the researchers will also develop an outreach program to help educate the public about stem cell and organoid research. They will create videos and a website on the Tomorrow Life platform, a science communication filmmaking initiative directed by Kiani.

Although the grant will focus on liver organoids, the researchers say that their findings could also inform the development of other types of human organoids, such as brain, kidney or retina.

Read this article:
UPMC-Pitt Researchers Receive Grant to Advance Liver Organoids - UPMC & Pitt Health Sciences News Blog - UPMC

Regenerative Medicine Market Size Worth $57.08 Billion By 2027: Grand View Research, Inc. – Markets Insider

SAN FRANCISCO, Aug. 12, 2021 /PRNewswire/ --The global regenerative medicine marketsize is expectedto reach USD 57.08 billion by 2027, growing at a CAGR of 11.27% over the forecast period, according to a new report by Grand View Research, Inc. Recent advancements in biological therapies have resulted in a gradual shift in preference toward personalized medicinal strategies over the conventional treatment approach. This has resulted in rising R&D activities in the regenerative medicine arena for the development of novel regenerative therapies.

Key Insights & Findings:

Read 273 page research report, "Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Cell-based Immunotherapies, Gene Therapies), By Therapeutic Category (Cardiovascular, Oncology), And Segment Forecasts, 2021 - 2027", by Grand View Research

Furthermore,advancements in cell biology, genomics research, and gene-editing technology are anticipated to fuel the growth of the industry. Stem cell-based regenerative therapies are in clinical trials, which may help restore damaged specialized cells in many serious and fatal diseases, such as cancer, Alzheimer's, neurodegenerative diseases, and spinal cord injuries. For instance, various research institutes have adopted Human Embryonic Stem Cells (hESCs) to develop a treatment for Age-related Macular Degeneration (AMD).

Constant advancements in molecular medicines have led to the development of gene-based therapy, which utilizes targeted delivery of DNA as a medicine to fight against various disorders. Gene therapy developments are high in oncology due to the rising prevalence and genetically driven pathophysiology of cancer. The steady commercial success of gene therapies is expected to accelerate the growth of the global market over the forecast period.

Grand View Research has segmented the global regenerative medicine market on the basis of product, therapeutic category, and region:

List of Key Players of Regenerative Medicine Market

Check out more studies related to Global Biotechnology Industry, conducted by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: 1-415-349-0058Toll Free: 1-888-202-9519Email: sales@grandviewresearch.comWeb: https://www.grandviewresearch.comFollow Us: LinkedIn| Twitter

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg

See more here:
Regenerative Medicine Market Size Worth $57.08 Billion By 2027: Grand View Research, Inc. - Markets Insider

Dissecting the Unusual Biology of the SARS-CoV-2 Delta Variant – The Scientist

SARS-CoV-2 is fitter than ever. Its latest incarnation, the Delta (or B.1.617.2) variant, is the fastest-spreading form of the virus yet. First identified in India, which it swept through killing hundreds of thousands this spring, Delta has swiftly become the most dominant coronavirus variant worldwide. While its already driving rapid increases in hospitalizations and deathsoverwhelmingly in unvaccinated populationssimply by virtue of being more transmissible, it may also cause more severe disease than some previously dominating SARS-CoV-2 variants.

Meanwhile, emerging data suggest that when vaccinated people become infected with the Delta variant and develop symptomswhich, although increasing in frequency, remains exceedingly rare, officials reportthey might be as contagious as unvaccinated infected people. Those findings motivated the Centers for Disease Control and Prevention (CDC) to recommend in late July that in places with high transmission of the virus, even fully vaccinated people should wear masks indoors.

The Delta variants emergence isnt a shock to many researchers; spreading throughout the globe for a year and a half, SARS-CoV-2 was destined to adapt to humans and become better at infecting them. The mystery remains, however, exactly how Delta affects the human body differently than other variants. A flurry of recent research, little of which has undergone peer review, is yielding some clueson how the Delta variant might produce greater amounts of virus in peoples airways, for instance, which could make it more transmissible, and how it could cause more severe disease.

Scientists are also uncovering cause for hope. Although the antibodies induced by vaccines available in the US are slightly less effective against the Delta variant, the shots are largely still powerful protectors against severe cases of COVID-19. And according to preliminary data, breakthrough infections in vaccinated people resolve faster than in unvaccinated people.

Weve already seen a variety of other variants that have somebut maybe not allof the same characteristics that Delta has, such as increased transmission and a slight reduction in the effectiveness of vaccine-induced antibodies, says Richard Kennedy, an immunologist at the Mayo Clinic in Rochester, Minnesota. None of those are really a surprise. This [variant] just seems to have more of all of those.

Measuring SARS-CoV-2s transmissibility in the real world is notoriously difficult as human behavior is continuously changing, notes virologist Paul Bieniasz of Rockefeller University, but the fact that the Delta variant has so quickly displaced its dominating predecessor Alpha (B.1.1.7) is convincing evidence that its able to spread more rapidly in incompletely vaccinated populations. The UK governments Scientific Pandemic Influenza Group on Modelling, Operational sub-group (SPI-M-O) estimates that Delta is between 40 and 60 percent more transmissible than the Alpha variant and nearly twice as transmissible as the original virus first identified in China.

In explaining this heightened transmissibility, scientists point to not-yet-peer-reviewed data suggesting that infection with the Delta variant results in greater levels of virus accumulating more rapidly in human airways. In China, researchers tracked 62 people exposed to the virus who developed infections with the variant. They took daily measurements of the concentrations of viral RNA in swabs from the backs of the participants throats. Compared to 63 people infected with other variants, people with Delta infections tested positive sooner: four days after viral exposure compared to six. And when patients infected with Delta first tested positive, they carried around 1000 times more viral RNA. Although virologist Angela Rasmussen of the University of Saskatchewans Vaccine and Infectious Disease Organization cautions that viral RNA isnt necessarily a proxy for the amount of virus that is actually infectious, its probably a safe assumption that people are making more virus and shedding more virus when infected with the Delta variant, she says.

Perhaps the variant replicates faster inside cells or binds more tightly to human cells ACE2 receptor, which the viruss spike protein uses to enter cells, Kennedy speculates. But much attention has surrounded a particular mutation on the Delta variant called P681R, which suggests another potential mechanism. The mutation lies at the junction between two subunits of SARS-CoV-2s spike protein, at a site that allows the human cellular enzyme furin to cleave the spike into two parts. This cleavage, some experiments suggest, primes spike proteins in a way that allows them to fuse more readily with a host cells membrane, according to a detailed description in Nature.

The Delta variants P681R mutation seems to allow that cleavage to occur more efficiently than in the original SARS-CoV-2 strain. This could help the variant infect more cells in a given amount of time, and therefore, make more copies of itself overall. Having a more efficient furin cleavage site could lead to increased amounts of virus in the respiratory tract, Bieniasz says. The Alpha variantalso more transmissible than other versions of SARS-CoV-2 when it first emergedhas a similar mutation.

Some scientists are skeptical that the P681R mutation is to blame for the heightened viral load in people infected with Delta. Kei Sato, a virologist at the University of Tokyo, says that in his own experiments, he and his colleagues generally didnt observe much difference in replication or the ability to infect cells when comparing the Delta variant to a previously described form of the virus that lacks the P681R mutation. In any case, Bieniasz says hed be surprised if the Delta variants heightened transmissibility were caused by P681R alone. The variant carries a handful of other mutations on the spike protein, and more scattered around the genome. But there isnt really any information at this point that would tell you mechanistically what their contribution is to the increased fitness of Delta, he says.

The fact that the Delta variant has also triggered increasing numbers of infections in vaccinated people has generated a bevy of headlines, some of which have been criticizedfor their alarmist nature. The CDCs revised guidelines on mask-wearing were based in part on data from an outbreak in Massachusetts in the wake of large public gatherings. In July, officials identified 469 people in Barnstable County who tested positive, mostly for the Delta variant (participants had likely asked to be tested, and the majority had developed COVID-19 symptoms). Three-quarters were fully vaccinated, in part reflecting a relatively high vaccination rate in the area. Scientists stress that the vaccines still work as intended; they were designed to prevent severe disease, not infections. The Massachusetts study, for instance, reported only five hospitalizationsfour in fully vaccinated peopleand no deaths.

Nationwide, robust figures on the frequency of breakthrough cases are elusiveparticularly of asymptomatic or mild cases; the CDC only monitors instances that have progressed to hospitalization or death. According to an unpublished internal CDC document obtained by ABC News, breakthrough cases are reported for 0.096 percentor 153,000of the 156 million Americans who are fully vaccinated. A recent review of data from 25 states also estimated the rate of breakthrough cases to be well below 1 percent. According to that same review, the rates of hospitalizations and deaths with COVID-19 among the fully vaccinated range from effectively zero to 0.06 percent and 0.01, respectively.

Surprisingly, the Barnstable County study detected similar amounts of viral RNA in the specimens of vaccinated and unvaccinated participants. While thats not necessarily reflective of the peoples capacity to infect others, it is indisputable that in this outbreak, there seems to be transmission between previously vaccinated people, says Hana Akselrod, an infectious disease physician at George Washington University. The fact that participants had been gathering in bars and other crowed spaces probably created a high-risk setting for viral transmission, she adds.

Kennedy cautions that its hard to say how much of the increase in breakthrough infections is because of the Delta variants specific biology, rather than simply because its dominating a general surge in cases. But recent CDC data from Colorado does suggest vaccines are less effective against the variant; when it sped through Mesa County, the overall effectiveness of the available vaccines against symptomatic infection dropped to 78 percent, while in counties with lower Delta levels, it was 89 percent.

The variants fitness advantage could feasibly allow it to build up a high viral load before vaccinated immune systems crank out enough antibodies to quash it, Akselrod says. Anatomically speaking, its possible that while antibodies induced by current vaccines form high, protective levels in the lungswhere infection is associated with severe COVID-19 symptomsthey might be less able to access mucosal tissues in the nose and upper respiratory tract, allowing viral replication to occur there, Bieniasz speculates.

Another possible factor in establishing infections in vaccinated people is the Delta variants modest ability to evade vaccine-induced antibodies, Akselrod suggests. One yet-to-be-peer-reviewed paper posted to medRxiv in mid-July pitted antibodies isolated from 40 healthcare workers who had received either the Pfizer-BioNTech or Moderna mRNA vaccines against different variants. They found the Delta variant reduces the ability of antibodies to neutralize the virus by around 2.5-fold compared to a previously described isolateslightly more so than the Alpha variant but not as much as the Beta variant (B.1.351) first discovered in South Africa or the Gamma variant (P.1) first spotted in Brazil.

This is likely due to mutations to the Delta variants receptor binding domainthe patch on the spike protein that latches onto host cells ACE2 receptors and is targeted by vaccines, Kennedy says. What happens is the antibody either doesnt bind or doesnt bind as well, he explains. But the human immune system typically produces many different antibodies against individual viral proteinsnot to mention other kindsof immune machinerypreventing a complete reduction in vaccine effectiveness.

To wit: data from the Sisonke clinical trial in South Africa, reported in a news conference on Friday, suggest that even when it comes to Delta, the Johnson & Johnson vaccine is 71 percent effective against hospitalization and 95 percent effective against death. Rasmussen says she expects future variants to arise for which current vaccines are less protective, but for now, the vaccines are actually holding up very, very well against Delta.

In line with that idea is unpublished data from Singapore posted to medRxiv on July 31 that tracked Delta infections in 88 vaccinatedand mostly symptomaticpeople. Although their viral RNA loads for the first week of illness were similar to those recorded in a group of 130 infected unvaccinated people, they decreased much more quickly in the vaccinated group. And it showed that they had a huge spike in neutralizing antibodies immediately on testing positive, adds Rasmussen, who wasnt involved in the research.

Even so, several experts, including Rasmussen, Sato, and Bieniasz, agree with the CDCs recommendation that vaccinated people should wear masks in high-risk settings. No one wanted to be spending the summer sweating under masks, but this is the situation we have now, and we have to protect each other, Akselrod says. The primary use of masks is to prevent infections among unvaccinated people who are more contagious for longer and are most at risk for developing severe COVID-19 with Delta.

Its not clear if the elevated risk of hospitalization and death that someepidemiological studies have linked to Delta has more to do with characteristics of the populations in which Delta is circulating, or with the biology of the variant, Akselrod says. But some researchers have explored possible biological explanations. In a recent preprint, the University of Tokyos Sato and his colleagues report that when they allowed a SARS-CoV-2 isolate to infect modified monkey cells in vitro, the cells would stick together, forming connected structures known as syncytia, which have beenspotted in the lungs of people with COVID-19. The team suspected that SARS-CoV-2s furin cleavage site might be facilitating the observed clumping.

In addition to helping the viruses fuse with cells, its plausible that cleavage of the spike protein could also somehow cause infected cells to fuse with other cells close by. Notably, the team saw that syncytia induced by the Delta variantwhose P681R mutation may allow for more efficient cleavagewere much larger than those induced by a different form of SARS-CoV-2 that lacks the mutation. Interestingly, hamsters infected with SARS-CoV-2 viruses engineered to express the P681R mutation showed more signs of obstructed airways, and lost weight more quickly, than those infected with the other version of SARS-CoV-2suggesting the variant caused more severe disease. Sato hypothesizes that by causing larger syncytia to form, the Delta variant could be causing more severe tissue damage in the lung. I think that is the reason why the P681R-bearing virus is more pathogenic, he says.

Rasmussen isnt fully persuaded that the Delta variant is inherently more pathogenic. After all, hamsters are imperfect models of human COVID-19. But the P681R-driven syncytia formation might somehow explain why the virus is more transmissible, she says. Some other viruses are known to use such fused structures to spread from cell to cell, sometimes allowing more rapid spread across tissues.

Meanwhile, Akselrod says shes worried about a Delta-driven surge of mostly young, unvaccinated people wholl develop long-term symptoms known as long COVID. Amid a depleted healthcare workforce, the COVID-19 recovery clinic she directs is still struggling to care for long COVID patients who were infected with the Alpha variant in late 2020 or early 2021. To think of getting another giant wave of Delta on top of that is just very, very sad, she says. Its still unclear, though, whether long COVID may be proportionally more frequent with Delta, and whether even vaccinated people could develop long COVID. Thats a big scientific unknown right now, she says.

As researchers continue to chip away at questions about Delta, theyre also keeping in mind the new variants that are likely on the horizon. I think well see more variants that have increased transmissibility. We may or may not see variants that cause more severe disease. . . . Well undoubtedly see variants that have an increased ability to evade immune responses, Kennedy says. Well run out of letters in the Greek alphabet before we run out of variants.

Continue reading here:
Dissecting the Unusual Biology of the SARS-CoV-2 Delta Variant - The Scientist

The anatomy of good health: | | azdailysun.com – Arizona Daily Sun

Chan refrains from focusing on weight loss in her practice. This is because the body is physiologically meant to survive, not lose weight. Rather, she helps her clients evaluate the role food plays in their lives along with nutritional counseling and meal preparation. Evolve Flagstaff also focuses on physical therapy and training.

Instead, Chan helps her clients embrace their body and learn fuel themselves to live life to the fullest.

"So much of our body shape and size is based on genetics, our economic situation, history so many different things that are completely out of our control that we may or may not be able to change our weight," Chan said. "Given the ideal environment of having access to food, to move or exercise and sleep enough will set you up in the genetic pool where you can actually let your genes express themselves.

However, that doesn't many people can't improve their nutritional intake.

According to Chan, many northern Arizonan diets don't get enough dietary fiber from not eating enough fruits and vegetables. This is even more common recently due to a surge in popuarlity in low-carb and keto diets. However, carbs are critical as they provide a good portion of fiber, nutrients and fuel for the body.

Northern Arizonans also have an inclination for plant-based, vegan or vegetarian diets. Chan said these options are fantastic, but people can become protein deficient without researching how to get enough plant-based protein into their diet or by working with a dietitian. Protein is necessary for muscle, neurochemicals, enzymes and hormones basically everything.

Read more:
The anatomy of good health: | | azdailysun.com - Arizona Daily Sun

Sandra Oh on the ‘Gift’ of ‘Grey’s Anatomy’ and Exploring Timely Topics on ‘The Chair’ (Exclusive) – Entertainment Tonight

Sandra Oh on the 'Gift' of 'Grey's Anatomy' and Exploring Timely Topics on 'The Chair' (Exclusive) | Entertainment Tonight arrow-left-mobilearrow leftarrow-right-mobilearrow rightGroup 7Gallery Icon Copy 2Video Play Button Copy 5Hamburger MenuInstagramYoutubeShare Button7C858890-6955-48EA-B871-66CE1E33590CVideo-Playbutton Copy Skip to main content

Read more from the original source:
Sandra Oh on the 'Gift' of 'Grey's Anatomy' and Exploring Timely Topics on 'The Chair' (Exclusive) - Entertainment Tonight